Zepbound for Sleep Apnea: What the Approval Covers, Trial Results and Medicare

Written by Nataliia Bondarchuk. Updated November 9, 2026.

Zepbound (tirzepatide) is FDA approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, used together with a reduced-calorie diet and more physical activity. The FDA granted that approval on December 20, 2024. In obstructive sleep apnea the airway repeatedly narrows or closes during sleep; doctors measure it with the apnea-hypopnea index (AHI), the number of breathing pauses and shallow-breathing episodes per hour. In the two SURMOUNT-OSA trials, people on Zepbound had about 25 to 29 fewer events per hour after a year, roughly a halving of their AHI, and they lost about 18% to 20% of their body weight. The approval does not cover sleep apnea in people without obesity, and neither the FDA nor the American Academy of Sleep Medicine (AASM) presents it as a straight swap for a CPAP machine. As of November 2026, Medicare Part D plans can cover Zepbound for OSA, but people with OSA cannot use the new $50-a-month Medicare GLP-1 Bridge.

The current label, revised August 2026, says the drug is indicated "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity," in combination with a reduced-calorie diet and increased physical activity. When the FDA announced the sleep apnea approval in December 2024, it described Zepbound as the first medication approved for OSA at that time. The label also carries a limitation of use: Zepbound should not be combined with other tirzepatide products, such as Mounjaro, or with any GLP-1 receptor agonist. How the two tirzepatide brands differ is covered in Mounjaro vs Zepbound.

Tirzepatide acts on two gut hormone receptors, GIP and GLP-1, which reduce appetite and slow stomach emptying; the mechanism is explained in how Zepbound works. In sleep apnea the benefit is thought to come mainly from weight loss, which is why the approval is tied to obesity.

Two conditions have to be met: a diagnosis of moderate to severe obstructive sleep apnea, and obesity. Sleep apnea is diagnosed with a sleep study, in a lab (polysomnography) or at home. The trials enrolled adults whose AHI was at least 15 on polysomnography, and the average AHI at the start was about 50 events per hour. The average body mass index (BMI) of participants was about 39.

The indication text in the label says "adults with obesity" and does not itself state a BMI number, so we do not give one here. In practice, your prescriber and, if you use insurance, your plan's coverage rules will decide whether you meet the criteria. People with diabetes were excluded from the trials.

SURMOUNT-OSA was two phase 3, double-blind trials published in the New England Journal of Medicine in 2024. A total of 469 adults were randomly assigned to Zepbound at the highest dose they could tolerate (10 or 15 mg) or to placebo for 52 weeks. Trial 1 included 234 people who were not using PAP; trial 2 included 235 people who were using PAP and kept using it, pausing for 7 days before each sleep study so the drug's effect could be measured on its own.

*Resolution was defined as an AHI below 5, or an AHI of 5 to 14 with an Epworth Sleepiness Scale score of 10 or less, meaning little daytime sleepiness. The figures above use the treatment-regimen estimand, which counts everyone randomized, including people who stopped the drug. Lilly's headline figure of "up to 51.5%" resolution comes from a different analysis, the efficacy estimand, which looks at people who stayed on treatment; on that basis AHI fell by 55.0% and 62.8% in the two trials. Numbers quoted online often differ for this reason, or because they give the difference from placebo rather than the raw change.

The trials were funded by Eli Lilly. Weight loss was gradual over the year, as described in how long it takes for Zepbound to work.

Yes. Trial 2 enrolled people who had used PAP for at least three months and kept using it. Their AHI, measured off PAP, fell by 29.3 events per hour on Zepbound against 5.5 on placebo, and half of them met the resolution criteria at one year compared with about 14% on placebo.

Not on its own say-so. In its approval announcement, the FDA called PAP "the standard of care for moderate to severe OSA." The AASM welcomed the approval as "a positive development" but said Zepbound "is only effective for cases of sleep apnea that are related to obesity" and "may not cure the disease," and that combining it with another therapy "may be ideal" for some patients. The AASM's 2026 fact sheet for clinicians describes Zepbound as "part of comprehensive OSA care along with positive airway pressure (PAP) therapy" and says "many patients will still need PAP."

What the AASM recommends instead of simply stopping is to "reassess PAP needs as AHI improves," and to consider a repeat home sleep test or lab study once your weight has stabilized at its lowest point. The fact sheet also notes there is "no head-to-head evidence" comparing Zepbound with PAP. In practice: keep using PAP, lose weight on treatment, then retest, and do not stop PAP without a new sleep study.

A preliminary SLEEP 2025 survey reported by HealthDay found doctors preferred CPAP (53% to 26%) while patients preferred Zepbound (48% to 35%).

Zepbound is a once-weekly injection under the skin. According to the label, treatment starts at 2.5 mg once weekly for 4 weeks; this starting dose is not a maintenance dose. The dose then goes to 5 mg and can be increased in 2.5 mg steps after at least 4 weeks on the current dose. For sleep apnea, the maintenance dose is 10 mg or 15 mg once weekly, and the maximum is 15 mg. Doses for weight management are compared in tirzepatide dosage from 2.5 mg to 15 mg.

Zepbound comes as single-dose pens or vials (2.5 mg to 15 mg per 0.5 mL), a multi-dose vial with 4 doses, and a single-patient-use KwikPen with 4 doses; the pen is described in our Zepbound KwikPen guide. Injection sites and technique are covered in where to inject tirzepatide.

Digestive side effects were the most common in SURMOUNT-OSA.

Zepbound has a boxed warning for thyroid C-cell tumors, and it must not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). The FDA also lists warnings for pancreatitis, gallbladder disease, low blood sugar, acute kidney injury, diabetic retinopathy in people with type 2 diabetes, suicidal thoughts or behavior, and pulmonary aspiration during anesthesia or deep sedation. That last warning matters for people with sleep apnea, who may be considering airway surgery: tell your surgeon and anesthesia team you take Zepbound well before any procedure. Practical tips for nausea and food choices are in best foods to eat on tirzepatide, and how long digestive effects tend to last is covered in how long tirzepatide side effects last.

It can. In January 2025, news reports from CNBC and BioSpace said CMS had confirmed that Medicare Part D plans can cover Zepbound for OSA. CMS guidance for Part D plans on the Medicare GLP-1 Bridge now lists moderate to severe OSA as a Part D-covered indication, naming Zepbound for OSA in adults with obesity as its example.

Whether your plan covers it, and at what cost, depends on its formulary and rules such as prior authorization. If your plan does not list Zepbound, CMS points beneficiaries with OSA to their plan's formulary exception process. Wider pricing and savings options are covered in how much Zepbound costs.

No. The Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027 and offers certain GLP-1 drugs for $50 a month for weight management. It covers only the Zepbound KwikPen, not single-dose pens or vials. Medicare's June 2026 fact sheet says that to qualify you must not have "moderate-to-severe sleep apnea," and that people who do should "contact your Medicare drug plan" because it "may already cover a GLP-1 drug for you." The $50 Bridge payment does not count toward the Part D deductible or the out-of-pocket cap.

SURMOUNT-OSA did not test what happens to sleep apnea after stopping. The AASM says the weight loss has to be maintained for the benefit to continue. Weight regain after stopping tirzepatide is discussed in what happens when you stop tirzepatide. If you stop, ask your doctor about a repeat sleep study and resuming PAP.

Zepbound is FDA approved for moderate to severe obstructive sleep apnea in adults with obesity, and in the SURMOUNT-OSA trials it roughly halved the number of breathing events per hour while producing about 18% to 20% weight loss. It works with or without CPAP, but the FDA calls PAP the standard of care, and the AASM advises retesting before dropping PAP. Label dosing reaches a maintenance dose of 10 mg or 15 mg weekly. As of November 2026, Medicare Part D plans can cover it for sleep apnea, while the $50 Bridge is not available to people with OSA.

This article summarizes published research and official guidance for general information and is not medical advice. The SURMOUNT-OSA trials were funded by Eli Lilly, the maker of Zepbound.